CompletedPhase 3

Intranasal Insulin for COVID-19-related Smell Loss

Mexico27 participantsStarted 2021-01-04

Plain-language summary

The aim of this study was to quantify the improvement in olfaction of 27 post-COVID-19 patients, after three intreventions of intranasal insulin during a four week period, with the help of the Threshold, Discrimination and Identification (TDI) score evaluated with Sniffin Sticks®.

Who can participate

Age range18 Years – 59 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * COVID-19 in the last 3 to 18 months and who persisted with anosmia, hyposmia or other olfactory dysfunction chronically and without improvement Exclusion Criteria: * nasal tumors, chronic sinusitis, drug-induced sinusitis, nasal polyposis, neurodegenerative disease, smoking, pregnancy Hypoglycemia and a previous diagnosis of diabetes mellitus or anatomical malformations such as septal deviation, rhinosinusitis or choanal atresia

What they're measuring

SMELL LOSS IMPROVEMENT

Timeframe: 1 MONTH

Trial details

NCT IDNCT05461365

SponsorUniversidad Panamericana

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-11-25

View on ClinicalTrials.gov More Anosmia trials